ArticleNeurology2022
Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 26 citations in OpenAlex.
- Sleep Fragmentation and Sleep Stages 1 and 2 Are Associated With Amyloid-Beta Burden in Cognitively Normal Older Adults.Journal of sleep research · 2026Trial
- Sex differences in the association between tau PET and cognitive performance in a non-Hispanic White cohort with preclinical AD.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Trial
- Observational
- Sequential associations of myelin dysfunction with Aβ and Tau pathology in Alzheimer's disease: a dynamic myelin perturbation.Alzheimer's research & therapy · 2026Article
- Multimodal Free-Water Imaging Links Cardiometabolic Risk to Periarterial Dysfunction and Amyloid Accumulation in Early Alzheimer's.Research square · 2026Article
- Neuropathological measures of increased tau phosphorylation across the Down syndrome lifespan.Acta neuropathologica · 2026Article
- Spatial coupling of enlarged perivascular spaces and white matter lesions across the Alzheimer's disease continuum.Frontiers in neuroscience · 2026Article
- Amyloid and tau pathologies are drivers of white matter damage in aging and Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer's Disease.Molecular neurodegeneration · 2025Article
- The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility: Questions and Debates.International journal of molecular sciences · 2025Review
- Article
- A novel approach to resilience and its links with education and Alzheimer's disease genetics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Integrating visual assessments and quantification methods for tau PET staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Characterizing visual read tau-PET-negative participants with Alzheimer's disease dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.JAMA neurology · 2025Article
- "Fill States": PET-derived Markers of the Spatial Extent of Alzheimer Disease Pathology.Radiology · 2025Observational
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Establishing tau-PET cut-points for cognitive diagnosis withImaging neuroscience (Cambridge, Mass.) · 2025Article
- Whole-brain functional connectivity predicts regional tau PET in preclinical Alzheimer's disease.Brain communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
objectiveIndividuals with biomarker evidence of β-amyloid (Aβ) deposition are increasingly being enrolled in clinical treatment trials but there is a need to identify markers to predict which of these individuals will also develop tau deposition. We aimed to determine whether Aβ-positive individuals can remain tau-negative for at least 5 years and identify characteristics that could distinguish between these individuals and those who develop high tau within this period.
methodsTau PET positivity was defined using a Gaussian mixture model with log-transformed standard uptake value ratio values from 7 temporal and medial parietal regions using all participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) with flortaucipir PET. Tau PET scans were classified as normal if the posterior probability of elevated tau was less than 1%. Aβ PET positivity was defined based on ADNI cutpoints. We identified all Aβ-positive individuals from ADNI who had normal tau PET more than 5 years after their first abnormal Aβ PET (amyloid with low tau [ALT] group) and all Aβ-positive individuals with abnormal tau PET within 5 years (biomarker AD). In a case-control design, logistic regression was used to model the odds of biomarker AD vs ALT accounting for sex, age,
resultsWe identified 45 individuals meeting criteria for ALT and 157 meeting criteria for biomarker AD. The ALT group had a lower proportion of DISCUSSION: Aβ-positive individuals can remain tau-negative for at least 5 years. Baseline characteristics can help identify these ALT individuals who are less likely to develop dementia. Conservative Aβ cutpoints should be utilized for clinical trials to better capture individuals with high risk of developing biomarker AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.